Plain-English answer
A citation should show the reader why a claim deserves confidence. If the claim is about a law, cite the law or agency explanation. If it is about spending, cite CMS or another data source with transparent methodology. If it is about clinical evidence, cite peer-reviewed research, systematic-review guidance, or reporting standards. If it is about payment, cite CMS, NHSA, payer policy, coverage decisions, or local reimbursement rules. If it is strategic inference, say it is inference and show the evidence base behind it.
Citation rules
| Claim type | Citation style | Example |
|---|---|---|
| Numerical claim | Link the exact dataset or official release. | CMS NHE for U.S. spending; NHC statistics for China institutions. |
| Regulatory pathway | Use regulator pages or guidance before secondary explainers. | FDA Device Advice, NMPA materials, official notices. |
| Payment or reimbursement | Cite payer, coverage, coding, payment, or procurement source. | CMS coding/coverage/payment guide, NHSA reports, local payer rules. |
| Clinical or public-health evidence | Cite studies, systematic reviews, reporting standards, or public-health agencies. | EQUATOR, CDC, AHRQ, WHO, peer-reviewed research. |
| Strategic interpretation | Use a source panel and name uncertainty. | Market-entry pages combining regulator, payer, hospital, and field evidence. |
Citation density
Not every sentence needs a footnote. Dense citation is important when a claim is current-sensitive, numerical, legal, regulatory, or controversial. Source panels are better for stable explanatory pages where the reader needs to know the source family rather than chase a citation after every sentence. A page should not use source clutter to hide weak reasoning. It should use citations to make the claim auditable.
When a page compares the United States and China, citations should generally be paired: one source family for the U.S. side and one for the China side. A comparison of regulatory pathways, for example, should not rely on FDA sources alone; a comparison of payment should not cite only CMS when the China side is about NHSA, local reimbursement, or procurement.
Pages should also avoid pseudo-citations. A homepage from an agency may establish that the agency exists, but it may not support a detailed claim about a specific rule. A news article can identify a controversy, but it should not replace the underlying policy document. A consulting report may be useful for market framing, but it is not a substitute for a payer policy, procurement notice, clinical study, or official dataset.
Examples
CMS's guide for medical technology companies is a good model because it separates coding, coverage, and payment. FDA Device Advice is appropriate for U.S. device-market pathway language. WHO's Data Quality Assurance material is useful when a page makes claims about routine health data quality. EQUATOR is useful when the issue is transparent reporting of research. CDC's ACIP GRADE materials and AHRQ methods guidance are useful when a page discusses certainty of evidence. These sources do different jobs and should not be used interchangeably.
Research anchors
- CMS guide for medical technology companies for coding, coverage, and payment distinctions.
- FDA Device Advice for U.S. device regulatory pathways.
- WHO Data Quality Assurance for routine health-data review principles.
- EQUATOR Network for transparent health-research reporting guidelines.
- CDC ACIP GRADE Handbook for evidence-certainty domains.